GlassScriptPhysician profile
Howard M Goldman
NPI 1699764175
$2,872.10
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $1,000 · 2021: $697.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $728.11 | 2019-2021 | |
| Janssen Biotech, INC. | $633.80 | 2019-2021 | |
| Leo Pharma INC. | $315.05 | 2019-2021 | |
| Journey Medical Corporation | $228.20 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $182.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $150.89 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $129.04 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.95 | 2019-2020 | |
| Almirall LLC | $74.54 | 2019-2020 | |
| Galderma Laboratories, L.P. | $72.20 | 2019-2021 | |
| Pfizer INC. | $53.20 | 2019 | |
| Lilly USA, LLC | $46.21 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $41.99 | 2019-2021 | |
| Genzyme Corporation | $40.74 | 2021 | |
| Genentech USA, INC. | $30.25 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $16.92 | 2021 | |
| Ucb, INC. | $16.11 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.